Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760086 | 0.80 | ESR1 (0.53) | ESR1ESR2RPS6KA3ABL1ABCB1 | |
| SCHEMBL27477478 | 0.80 | AHR (0.60) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL27928527 | 0.80 | ESR1 (0.57) | ESR1ESR2RPS6KA3ABL1ABCB1 | |
| SCHEMBL11693196 | 0.78 | ESR1 (0.52) | ESR1ESR2RPS6KA3 | |
| SCHEMBL3684267 | 0.76 | ESR1 (0.70) | ESR1ESR2PTGS2PTGS1 | |
| SCHEMBL7778555 | 0.76 | HSD17B10 (0.54) | ESR1ESR2ABL1ABCB1BCR | |
| SCHEMBL1759436 | 0.75 | ESR2 (0.47) | ESR1ESR2RPS6KA3ABL1ABCB1 | |
| SCHEMBL322288 | 0.73 | ESR1 (0.61) | ESR1ESR2RPS6KA3 | |
| SCHEMBL17217161 | 0.73 | ESR1 (0.52) | ESR1ESR2 | |
| SCHEMBL29434869 | 0.73 | ESR1 (0.52) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011057956-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057993-A1 | INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057956-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ESR1 2879/4885ESR2 1148/4885RPS6KA3 1212/4885 |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | ESR1 2879/4885ESR2 973/4885RPS6KA3 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.